Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis
| Autor: | Daniel Pink, Peter Reichardt, Per-Ulf Tunn, Stephan Richter, Gerhard Ehninger, Christoph Busemann, Dimosthenis Andreou, Sebastian Gerdes, Markus K. Schuler |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Adolescent endocrine system diseases Docetaxel Deoxycytidine Disease-Free Survival Sarcoma Epithelioid sarcoma Gemcitabine Docetaxel Chemotherapy Combination chemotherapy Soft tissue sarcoma Palliative chemotherapy Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Anthracyclines ddc:610 Survival rate Retrospective Studies business.industry Soft tissue sarcoma Sarcoma Retrospective cohort study Combination chemotherapy General Medicine Middle Aged Sarkom Epithelioides Sarkom Gemcitabin Docetaxel Chemotherapie Kombination Chemotherapie Weichteilsarkom Palliative Chemotherapie medicine.disease Gemcitabine Survival Rate Regimen Treatment Outcome Female Taxoids business medicine.drug |
| Zdroj: | Oncology. 87:95-103 |
| ISSN: | 1423-0232 0030-2414 |
| DOI: | 10.1159/000362602 |
| Popis: | Objective: Epithelioid sarcoma (ES) presents unique clinical features in comparison to other sarcoma subtypes. Data regarding the benefits of chemotherapy are very limited. Combination regimens using gemcitabine and docetaxel (Gem/Doce) have proven to be effective, especially in uterine and nonuterine leiomyosarcoma. Yet, there is no available data on the efficacy of Gem/Doce in ES. Methods: A retrospective analysis of the three participating institutions was performed. Twenty-eight patients with an ES diagnosis presented at one of the participating institutions between 1989 and 2012. Of this group, 17 patients received chemotherapy. Results: Patients' median overall survival (OS) after the beginning of palliative chemotherapy was 21 months, and the 1-year OS was 87%. Twelve patients received Gem/Doce with a clinical benefit rate of 83%. The median progression-free survival (PFS) was 8 months for all patients receiving Gem/Doce. The best response was complete remission in 1 patient and partial remission in 6 patients. All 6 patients receiving Gem/Doce as a first-line treatment showed measurable responses with a median PFS of 9 months. Conclusions: In this retrospective study, Gem/Doce was an effective chemotherapeutic regimen for ES. Prospective studies are needed to better assess the effects of this combination drug therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|